

Graves Ophthalmopathy Pharmaceutical and Healthcare Pipeline Review H2

Graves Ophthalmopathy Treatment Pipeline Review H2 2017

PUNE, INDIA, January 6, 2017
/EINPresswire.com/ -- GET SAMPLE REPORT @

<https://www.wiseguyreports.com/sample-request/535865-graves-ophthalmopathy-pipeline-review-h1-2016>

Graves' Ophthalmopathy - Pipeline Review, H1 2016
Summary


The report provides comprehensive information on the therapeutics under development for Graves'

Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy
- The report reviews pipeline therapeutics for Graves' Ophthalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

- The report reviews key players involved Graves' Ophthalmopathy therapeutics and enlists all their major and minor projects
- The report assesses Graves' Ophthalmopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Graves' Ophthalmopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Graves' Ophthalmopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=535865

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Graves' Ophthalmopathy Overview 6

Therapeutics Development 7

Pipeline Products for Graves' Ophthalmopathy - Overview 7

Graves' Ophthalmopathy - Therapeutics under Development by Companies 8

Graves' Ophthalmopathy - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Graves' Ophthalmopathy - Products under Development by Companies 11

Graves' Ophthalmopathy - Companies Involved in Therapeutics Development 12

Genmab A/S 12

Neothetics, Inc. 13

Novartis AG 14

Yuhan Corporation 15

Graves' Ophthalmopathy - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Combination Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

(fluticasone propionate + salmeterol xinafoate) - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/535865-graves-ophthalmopathy-pipeline-review-h1-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.